Pfizer heart pill to be standalone therapy

July 26, 2006

U.S.-based Pfizer Inc., the world's largest pharmaceutical company, says it has decided to sell a new heart treatment medication as a standalone pill.

Pfizer initially announced it would sell the new drug, torcetrapib, only in combination with Lipitor, the company's best-selling cholesterol treatment medication, The New York Times reported. That decision produced strong opposition from physicians.

Torcetrapib, still being tested in clinical trials, is at least 18 months from receiving federal approval. But initial trial results indicate the drug substantially raises the levels of so-called good cholesterol -- a novel approach to preventing heart attacks and strokes, the Times said.

If Pfizer had offered torcetrapib only in a combination pill, that would have forced patients taking other cholesterol-lowering statins -- such as Merck & Co. Inc.'s Zocor -- to switch to Lipitor to obtain torcetrapib's benefits.

If proven effective, industry observers say the drug could potentially garner several billion dollars annually in sales.

Copyright 2006 by United Press International

Explore further: Pfizer's 2Q profit sinks 79 pct but tops forecasts

Related Stories

FDA adds heart warning to Pfizer anti-smoking pill

June 16, 2011

(AP) -- Federal health regulators are warning doctors and patients that Pfizer's anti-smoking drug Chantix may slightly increase the risk of heart attack and other cardiovascular problems.

Hormone-blocking drug reduces breast cancer risk

June 4, 2011

(AP) -- Millions of women at higher-than-usual risk of breast cancer have a new option for preventing the disease. Pfizer Inc.'s Aromasin cut the risk of developing breast cancer by more than half, without the side effects ...

UNICEF discloses vaccine prices for 1st time

May 29, 2011

UNICEF is for the first time publicizing what drugmakers charge it for vaccines, as the world's biggest buyer of lifesaving immunizations aims to spark price competition in the face of rising costs.

Recommended for you

Scientists discover key clues in turtle evolution

September 2, 2015

A research team led by NYIT scientist Gaberiel Bever has determined that a 260-million year-old fossil species found in South Africa's Karoo Basin provides a long awaited glimpse into the murky origins of turtles.

For 2-D boron, it's all about that base

September 2, 2015

Rice University scientists have theoretically determined that the properties of atom-thick sheets of boron depend on where those atoms land.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.